3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lymphoma
9
Lymphoma, Non-Hodgkin
7
Lymphoma, Follicular
6
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Neoplasms
3
Melanoma
3
Lymphoma, B-Cell
3
Hodgkin Disease
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lymphoproliferative Disorders
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Triple Negative Breast Neoplasms
1
Sezary Syndrome
1
Sarcoma, Clear Cell
1
Pancreatic Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Microsatellite Instability
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
alectinib
3
entrectinib
2
atezolizumab
2
trametinib
1
pertuzumab
1
enzalutamide
1
dabrafenib
1
cobimetinib
1
capmatinib
1
abexinostat
1
Vemurafenib
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
atezolizumab
×
Lymphoid
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled